Fluvastatin Sodium Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Fluvastatin Sodium Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
96
Registered trials
11
Result records
21
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Fluvastatin Sodium can convert its Small molecule drug profile and HMGCR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Fluvastatin Sodium (query alias: fluvastatin) |
|---|---|
| Modality / target | Small molecule drug; HMGCR; HMG-CoA reductase inhibitors |
| Highest global status | Approved |
| Originator | Novartis Pharma AG |
| Active developers | AstraZeneca PLC, Pierre Fabre SA, Tanabe Pharma Corp. |
The MCP disease footprint includes Atherosclerosis, Dyslipidemias, Hypercholesterolemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTR20260346 | Not Applicable | 已完成 | 92 | Not disclosed |
| CTR20253523 | Not Applicable | 已完成 | 72 | Not disclosed |
| CTR20253730 | Not Applicable | 已完成 | 46 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
The Effects of Single Dose Rifampin on Pharmacokinetics of Fluvastatin in Uninduced and Hepatically Induced Healthy Volunteers
Phase 4; n=10; evaluation: not stated. Reported fields: AUC(Mean) = 642 ng/mL·h (Standard Deviation, 269); AUC(Mean) = 371 ng/mL·h (Standard Deviation, 217); AUC(Mean) = 124 ng/mL·h (Standard Deviation, 33.7)
An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Phase 3; n=18; evaluation: not stated. Reported fields: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis(Least Squares Mean) = -4.1 percent change (Standard Error, 9.0); -; -
A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer.
Phase 2; n=33; evaluation: not stated. Reported fields: CC3 positivity = 2.7 fold increase (95%CI, 1.9 - 5.0)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Fluvastatin Sodium addresses Atherosclerosis, Dyslipidemias, Hypercholesterolemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 21 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: HMGCR records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-03-18 | 科兴制药与常州制药厂达成两款心血管药物欧洲商业化合作 | Approved | Financial terms not disclosed |
| 2026-03-11 | Hyundai Pharm partners with Daiichi Sankyo Korea to sell Mevalotin | Approved | Financial terms not disclosed |
| 2022-04-29 | Daewoong to cooperate with AZ in launching hyperlipidemia in Asia | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Fluvastatin sodium sustained release tablet and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Repurpose of fluvastatin for treatment of osteoporosis”. The milestone feed surfaced a patent-application signal described as “Synthesis method of fluvastatin sodium key intermediate”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
